Priyanka Jain, Co-Founder and CEO of Evvy, joins Bryan Mahoney to unpack how she built the world’s largest real world data set on the vaginal microbiome, a category almost nobody was building. They cover why community and education became Evvy’s entire growth engine, the venture funding gap facing women’s health founders, and what Priyanka says about raising money as a founder in an underfunded space.
Behind the Expert
Priyanka Jain didn’t come to women’s health from medicine — she came to it from data. She studied data science and machine learning at Stanford, then spent roughly a decade in New York’s machine learning ecosystem, most recently at a data science company working to remove bias from the hiring process so it would be fairer to women. That focus has been the through line of her life, from building schools for girls in countries where they lacked access to education to helping college women prepare for interviews and land the jobs they wanted. Her own experience as a patient with an autoimmune condition — thirty tubes of blood, every scan, and a steady stream of “your results are normal” — turned that lens on healthcare. Five years ago she co-founded Evvy, a precision women’s health company focused on the vaginal microbiome, which today serves more than 100,000 patients, works with more than 2,000 doctors across the US, and reaches over 200 million views a year with its educational content.
The Quick Hits
- Jain treats women’s health as a data problem. Women weren’t included in US clinical research until 1993, and they are still diagnosed on average four years later than men across more than 700 of the same diseases — because health has largely been defined by what predicts it in the male body.
- The vaginal microbiome is an overlooked, under-measured set of biomarkers. Vaginal discomfort is the leading reason women seek healthcare advice in the US, and Jain points to research linking disruptive bacteria to inflammation across the reproductive tract, with implications for fertility, pregnancy, and beyond.
- The market wasn’t missing demand — it was missing information. Women were already searching and asking each other in online communities; they were mostly met with ads for products, not science or data.
- Education is the sales strategy. Once someone understands that she has a vaginal microbiome and that a clinically validated way to measure it exists, Jain says, the product largely sells itself — and Evvy’s content now draws over 200 million views a year across SEO, AI search, and TikTok.
- Data changes how communities talk. In Reddit threads and Facebook groups for recurring and chronic conditions, the first reply to a new post is now often “what are your Evvy results?” — an objective starting point in place of guesswork.
- The funding gap is real and it’s also the opportunity. By Jain’s numbers, only about 1% of global biopharma R&D and around 3% of digital health venture dollars go to women’s health, with 60–70% of that concentrated in fertility and pregnancy — while women control roughly 80% of healthcare spend.
- A founder doesn’t have to be every expert. Jain’s answer to critics asking what letters come after her name: her job is to bring the attention, funding, and people together, not to be each of those people.
“Where is the data?”
Jain’s path into vaginal health started with frustration as a patient. Living with an autoimmune condition, she saw every doctor she could find in New York, had thirty tubes of blood drawn, and went through every scan and test she was told to take — only to hear, again and again, that her results were normal and nobody knew what was wrong. The guidance she got was a list of maybes: stress, water, sleep.
Digging into the research herself, she learned that women weren’t part of US clinical research until 1993, and that women are still diagnosed on average four years later than men across more than 700 of the same diseases. To someone trained in data science and machine learning, that read less like an unsolvable medical mystery and more like a measurement gap: the female body gives off signals that simply aren’t being tracked.
Why the vaginal microbiome
Evvy zeroed in on the vaginal microbiome as the clearest example of an overlooked biomarker. On one side, vaginal discomfort is the leading reason women seek healthcare advice in the US, and Jain says women are more likely to be misdiagnosed than correctly diagnosed when they go to the doctor for it. On the other, she points to a body of research showing that disruptive, infectious bacteria are associated with inflammation of the reproductive tract — with links to fertility outcomes, preterm birth, cervical cancer progression, menopause symptoms, and endometriosis relapse.
The “microbiome” label has been both a blessing and a curse. Advances in gut, oral, and other microbiome science have built the tools and brought costs down — but many doctors and patients have also been let down by microbiome products that weren’t clinical. Jain is emphatic that Evvy is: testing is ordered by licensed clinicians, and patients receive real diagnoses and prescribed treatment. She believes the vaginal microbiome will be the first to translate into true clinical care, precisely because doctors are already trying to test for what’s going on — they just haven’t had microbiome-based tools to do it.
The market was already looking
Bryan assumed a company creating a new category would have to pull customers toward it. Jain pushes back: women were already searching for answers, already asking each other in online communities, and already being targeted — mostly with products promising to make them smell like a flower rather than anything grounded in science. Because the topic is stigmatized, people assume the problem is rare or personal. In reality, she notes, about 30% of women have at least one vaginal infection at any given time.
Education as the entire growth engine
For Evvy, community, content, and education aren’t a supporting channel — they are the marketing strategy and the sales strategy. The job is to teach women that they have a vaginal microbiome, that it relates to the things they already care about, and that a clinically validated way to understand it exists. The team’s content — the kind of thing Jain says women should have learned in sex ed and didn’t — draws over 200 million views a year and performs across traditional SEO, AI search, and TikTok.
Community works on two levels. Evvy runs its own presence on TikTok and Instagram plus a private Facebook group, but some of the most telling signals come from third-party communities on Reddit and Facebook where women dealing with recurring or chronic issues compare notes. There, the conversation has started to anchor on data rather than anecdote.
Raising money in an underfunded category
Jain is direct about the numbers. By her count, less than 2% of venture dollars go to women; only about 1% of global biopharma R&D spend goes to women’s health; NIH funding for women’s health has historically sat somewhere between 4% and 7%; and just 3% of digital health venture dollars go to women’s health — 60 to 70% of which is focused solely on fertility and pregnancy. Personally, the pushback was pointed: a day after Evvy launched, an OB-GYN published a takedown questioning what founders without MDs or PhDs could possibly have to say about healthcare.
Her reframe is that the system won’t be rebuilt only by the experts inside it — it needs the women experiencing it to demand something better, and founders willing to persist and bring the right experts together. And the funding gap cuts both ways: women are half the population and control around 80% of healthcare spend, which means the underinvestment is also a large, underserved market.
What’s next for Evvy
Five years in, Evvy serves over 100,000 patients and works with more than 2,000 doctors across the country. Jain says announcements on the growth of the business are coming in the months ahead, along with results from a prospective study using Evvy’s test in IVF clinics — and ways fertility patients and doctors may be able to use the platform to help improve outcomes. Her closing note was aimed at other builders.
Sound Bites
- “I was sitting here thinking, how on earth is this the best guidance that you can give me? Where is the data?”
- “Fundamentally, we have defined health and disease based on what predicts health and disease in the male body. And the female body is different down to the cellular level.”
- “We are not living in kombucha land over here. Everything we do is ordered by licensed clinicians. We’re prescribing real treatment. We’re giving patients real diagnoses.”
- “The thing people don’t realize is that the market is begging and looking. And so we are just meeting them with the thing that they’ve been looking for.”
- “Community, content, education — that is our marketing strategy. That’s our sales strategy. But at the same time, what’s so fun about that is that we get to educate women about their bodies.”
- “What we often see is that the first comment on somebody’s new post will be, well, what are your Evvy results? Where is the data that you’re using to solve this?”
- “It’s my job to bring the attention, the awareness, the funds, the people together to solve this, but I don’t need to be each of those people.”
The Chord take
Evvy’s growth story is easy to misread as a content-marketing playbook. It’s more fundamental than that. The demand already existed — women were searching, asking, and comparing notes — but the category had no shared, objective starting point. Evvy’s education does the work of naming the thing people were already experiencing, and its data gives them a common language to talk about it. The clearest sign the strategy works isn’t the 200 million views; it’s strangers in a Reddit thread asking each other for their results before offering advice. That’s the same pattern Chord sees across commerce and AI: tools only become useful when they’re grounded in the right context. Jain’s critique of women’s healthcare is, at its core, a critique of models built on incomplete data — health defined by what predicts it in the male body — and of decisions made confidently on top of those gaps. Her answer isn’t to replace clinicians with an algorithm. It’s to measure what’s been ignored, put it in front of licensed clinicians who make the call, and let patients bring better information into the conversation. For founders in any underfunded or stigmatized category, the lesson is twofold. An underinvested market isn’t necessarily a small one; sometimes it’s a large one nobody has bothered to measure. And growth can come from earning trust through education rather than buying attention — but only if what you’re educating people toward is real, rigorous, and backed by data.
Put it to work
- 1Before assuming you need to create demand, look for where it already lives. Search behavior and community threads often reveal people actively looking for answers they haven’t found — your job may be to meet them, not convince them.
- 2Treat education as a growth channel with real goals, not a brand afterthought. Content that teaches people something they genuinely wish they’d learned earlier compounds across search, AI-driven discovery, and social.
- 3Give your community something objective to anchor on. When customers can share data — results, measurements, outcomes — conversations move from anecdote to comparison, and your product becomes part of the vocabulary.
- 4Audit your data for who it leaves out. Jain’s point about health applies broadly: models and AI tools trained on incomplete data will reproduce the gaps already in it. Know what your data doesn’t measure before you trust what it predicts.
- 5Separate your role from the experts’ roles. If you’re building in a specialized field without the credentials, your leverage is in assembling the right people, funding, and attention — and letting their expertise lead where it should.
- 6If you’re raising in an underfunded category, lead with market size, not just the gap. Underinvestment is a headwind and an argument — pair the stats on what’s missing with the scale of the need.
Full transcriptShow ↓
Bryan Mahoney
Hey everyone, welcome back to another episode of the Brilliant Commerce Podcast, where I have a chance to sit down with some of the brightest minds in commerce and unpack what it takes to build iconic or, what I like to say, next-to-be-iconic brands. And I'll be honest with everyone today, as I just was honest with you, Priyanka. Today is a bit of a first for me on the podcast. I'm sitting down with a founder who has built a company in a category that most people, myself included, are not totally educated about. And it is not directly and squarely placed in commerce, but there's still a ton to learn about.
Bryan Mahoney
And so this morning I'm joined by Priyanka Jain, who is co-founder and CEO at Evvy, a precision women's health company that has built the world's most advanced platform for vaginal health, including what I'm told is the world's largest real-world data set on the vaginal microbiome. Man, I have so much to learn. So let's get going. Priyanka, thank you so much for being here with us this morning.
Priyanka Jain
Thank you for having me. I'm so excited for our conversation.
Bryan Mahoney
Yeah, long time coming. We've been going back and forth, but we finally made it happen. I normally get warmed up here just by asking, where am I finding you today?
Priyanka Jain
In New York City. Our office is here in the city, and the vast majority of our team, so we're very lucky to be in this amazing place.
Bryan Mahoney
Yeah, it's warm. We're recording on July the 15th. So I would imagine it's properly summer in New York today and you're feeling it.
Priyanka Jain
Yes, I think today we're actually in a heat wave. I think it's supposed to be 100 degrees today. So I'm staying inside.
Bryan Mahoney
Okay, well, that's on brand for New York. Let me ask you to take a couple of minutes and tell me your story. Tell me the story about what led you to start a company that was focused on vaginal health, of all things.
Priyanka Jain
Yeah, absolutely. So I guess most people don't wake up every day thinking about the vaginal microbiome, nor did I until five years ago. But I'll start by saying my background is not in health care. My background is in data science and machine learning. That's what I did at Stanford. And then I've been in the machine learning tech ecosystem here in New York for the past 10 years. And simultaneously, while I've been in these data science companies, I have had so many of my own health challenges as a female patient.
Priyanka Jain
For me, I have an autoimmune condition. I have been to every doctor in New York. I have drawn 30 tubes of blood. I have done every scan, every test that people could tell me to do. And no matter what I did, doctors would always call me and tell me, your results are normal. We don't know what's wrong. We don't know if it's progressing. We don't know if it's getting better. Maybe you're stressed. Maybe you need to drink more water. Maybe you need to sleep more. And I was sitting here thinking, how on earth is this the best guidance that you can give me? Where is the data? I had a very visible autoimmune condition.
Bryan Mahoney
That's a lot of maybes too. It's like, okay, can we get to the bottom of this maybe?
Priyanka Jain
Yes, everything was a maybe. It was like 30% chance this, 30% chance that, 30% chance this. I was like, okay, so we have no idea. And it was just this constant unexplained, I don't know. And as I dug into the research myself, as I think so many women end up doing, that's when I found out that women in the US were not in clinical research until 1993. And that to this day, women are diagnosed on average four years later than men across over 700 of the same diseases. And that's when I realized it's actually a really interesting data problem.
Priyanka Jain
Fundamentally, we have defined health and disease based on what predicts health and disease in the male body. And the female body is different down to the cellular level. And there are so many biomarkers and signals that our bodies are giving off, trying to tell us where we need help, what's going well, what's going on in our bodies. But we just don't measure and track those things because we just never studied women. And so I found that really interesting. And I thought there must be this huge opportunity that exists in these overlooked, under-leveraged female biomarkers. So what if we started to measure and track those biomarkers? Could we finally do a better job improving our ability to predict risk and diagnose and treat conditions as they uniquely manifest in women?
Priyanka Jain
And so obviously that's what we do today. We've zeroed in on the vaginal microbiome as a perfect example of what I'm describing, where on one hand, vaginal discomfort is the leading reason that women seek healthcare advice in the US. And when we go to the doctor, we are more likely to be misdiagnosed than correctly diagnosed. And then we are more likely not to get better than to get better. I mean, that's embarrassing.
Priyanka Jain
And then on the flip side, and what I found so interesting from a data standpoint, is that there are so many studies that show that when you have this disruptive, pathogenic, infectious bacteria in the vagina, not only do you have symptoms and infections, but you now also have infection and inflammation of the reproductive tract, which unsurprisingly affects fertility outcomes, whether that's infertility, IVF failure, recurrent pregnancy loss. It affects preterm birth, affects cervical cancer progression, affects menopause symptoms, endometriosis relapse. I mean, basically, if it has to do with the reproductive system's inflammation, the vaginal microbiome is modulating it. And I just couldn't believe that nobody was using that data set in women's health care today for the number one reason we go to the doctor, or to predict and improve outcomes across the female lifespan. So that's how I ended up in the space, and it felt like a really important set of biomarkers for us to finally pay attention to.
Bryan Mahoney
I mean, I think it's fascinating. I think it's unfortunate too. And I'm sorry you heard all of those maybes before finally getting to a place where you're like, I'm going to solve this. And obviously, I think the data science background is one that is interesting. It speaks to your curiosity, but also expertise around these large data sets. But you've also been involved in women's equity issues, if my research is correct, since you were quite young. So is it really the marriage of those two things? It feels like you were purpose-built for this and you almost had to start it.
Priyanka Jain
It's funny. I joke that the through line of my entire life is just women. It's like, how do we make the world a better place for women, whether it was building schools for girls in countries where girls didn't have access to school, or helping girls in college get better jobs and prep for interviews and get into the corporate world that they wanted to be in. The data science company I was at before Evvy was trying to remove bias from the hiring process to make the hiring process more fair for women.
Priyanka Jain
And so I've always been really interested in the ways that the system is structurally biased. Especially in the data world, so much of the data in general in the world is based on men. And so as we adopt all of these ML and AI tools, how much are we going to perpetuate the problems that we already have? How do we mitigate that? That's always been a really interesting problem to me. And I think that the health side of it was very much the coalescing of my own personal experiences and just the incredible, unbelievable frustration that it is to frankly be a woman going to the doctor. It's embarrassing, the state of the union, and I think that data is going to be a huge part of changing that.
Bryan Mahoney
Yeah, I love that. There's a few things that I want to ask you. I'm trying to figure out the best direction to go in. One of the things that I loved reading in some of my notes getting prepared for this is that you're truly using data in ways that make the world a better place. So much of what anyone working in technology is doing these days is within AI. And I love finding examples of where AI makes the humans in the loop better, or where we make the world a better place, as opposed to the pessimistic view. And it seems like this is definitely a wonderful story there.
Bryan Mahoney
So maybe let me start with the founder lens here, because I get this question an awful lot, which is like, man, being a founder seems super fun, and starting something must be great, and I want to be a CEO. And it seems to me like you are exactly where you should be. Everything that you are interested in and the work that you have done — you could not find a better person to be the CEO of the company that you find yourself at. But the other advice that I give people is that sometimes being an entrepreneur or being a founder is not something that is a choice you make as much as it is an addiction, to some extent. Do you love being a CEO? What advice would you have for a younger version of yourself? What do you know now that you didn't know then, that you would maybe do differently?
Priyanka Jain
I mean, I'm laughing because the first thing you said, which is that you're the perfect person to run this company, is definitely not what the perception was of me starting up Evvy. Actually, interestingly, we launched the company five years ago yesterday. I was doing a little bit of reflection.
Bryan Mahoney
Happy anniversary.
Priyanka Jain
Thank you. And I actually think one day later, basically, an OB-GYN in this space wrote this whole takedown article of us and was like, who are these founders who think that they have anything to say about healthcare? They're not doctors, they're not PhDs. And so I say that to say, I think that people did not look at me and say that you're the right person to run this company. What are the letters after your name that qualify you to do this? I mean, it's not fun being a young female founder raising money for a vagina company and trying to change the status quo for the number one reason that women go to the doctor when I don't have those letters after my name.
Priyanka Jain
And I think a lot of the uphill battle that I fought was saying that actually, I am a human, I'm a patient myself, who interacts with lots of other forms of services and technology and has a way better experience than I do when I go to the doctor. And why is that? And how can I elevate the experience of being a woman who goes to the doctor from the perspective of a consumer and a patient? And can I bring together the world's greatest experts to help solve this problem? I feel so honored and energized by the incredibly brilliant doctors and scientists that work on Evvy today, and those people might not be working on this problem if we hadn't started this company. If we hadn't raised the money and brought the attention to this problem, maybe those people would be doing something else.
Priyanka Jain
And so I often have to remind myself that it's my job to bring the attention, the awareness, the funds, the people together to solve this, but I don't need to be each of those people. Obviously, being a founder, there's constant imposter syndrome. I think especially in healthcare, it's really easy to feel that amplified. But my advice is, at the end of the day, the system is not going to be rebuilt just by the experts within it. We need new points of view. We need the women who are experiencing the system to be the ones who are demanding for it to be different and better. And so I think that you just have to be willing to persist through that, and bring together the experts who can help you build the right thing, but be okay with the fact that you might not be that expert yourself.
Bryan Mahoney
Well, I think that's the key right there. To me, however many years — 30 years into being a founder — I still wake up every day with imposter syndrome. And I do use it as motivation and energy. I have always found that the number one antidote for imposter syndrome is just not having an ego. And I think the last thing you said there is, I don't need to be the best at each one of those things. I'm not pretending to be the expert there, but I'm the person who's going to solve this — or myself and my co-founders are going to solve this — by bringing these people together, experts in the field, and asking the questions and not accepting the status quo and raising the money.
Bryan Mahoney
I'd be curious, what do you think is harder? So much of what you did was creating this category, trying to find customers who weren't necessarily looking for what you were offering. That is incredibly difficult, I would imagine. But also raising money in this environment, today and five years ago, as a female founder is something we don't talk about enough — also super, super difficult. So force rank that for me. What was harder, raising the money or creating the category?
Priyanka Jain
So interestingly, women actually were looking for this solution. I think what's really interesting is that, again, this is the number one reason women go to the doctor, and you do not get better when you go to the doctor today. And so guess what? Women are online. They're in online communities asking each other about different solutions. They're searching. I mean, these are some of the most searched terms on Google, and they're being hit by ads for products that make your vagina smell like a flower, and no health care and no science and no data. And what women really want is to know what's going on. Why is this happening? How do I get to the root cause? They don't want band-aids. Or they want band-aids in the short term, but then eventually people want to solve the problem.
Priyanka Jain
And I think this goes to the fact that we're solving this really taboo and stigmatized problem, where people assume that this must be me. Sure, you must be having to pull customers towards you, when in reality, if you look at the exits that have happened in women's health, they're almost all companies that sold products for vaginal odor, because it's such a common problem that has really no good solutions. And 30% of women at any given time have at least one vaginal infection. So it's a very, very prevalent problem. Honestly, once patients realize they have a vaginal microbiome and that Evvy exists, often the product sells itself.
Priyanka Jain
And our job is to educate women that they have a vaginal microbiome and that Evvy exists. And what are all the ways in which we can do that? I think our team has done a phenomenal job building an education platform. I think we get over 200 million views a year on our content that educates women about their vaginal health, their health more broadly, and teaches us things that we should have learned in sex ed, but we just never did. And that type of content does really well in SEO, in AI SEO, on TikTok, you name it. And so that's been our strategy on that side. And of course it's been extremely hard, but I think the thing people don't realize is that the market is begging and looking. And so we are just meeting them with the thing that they've been looking for. There's a lot more I can say there, but I'll pause there for a second.
Priyanka Jain
On the fundraising side, I would say that yes, objectively the stats are a bit small. I think it's something like less than 2% of venture dollars go to women. Even if you look at the way that healthcare dollars are distributed globally, if you look at biopharma R&D spend, only 1% of that goes to women's health globally. In the US, I think it's somewhere between 4 and 7% of NIH funding that has gone to women's health, across administrations. It's always been bad, to be honest, although obviously right now it's at the worst it's ever been.
Bryan Mahoney
Yeah, it's extra bad.
Priyanka Jain
But then even when you look at the private sector from a venture standpoint, only 3% of venture dollars in digital health have gone to women's health. And within that, 60 to 70% are focused solely on fertility and pregnancy — so our ability to reproduce — let alone every other part of our health that needs solutions and services. And so I say that to say it's massively underinvested in. But the flip side of that is it means there's a ton of opportunity. Women are half the population. We have so many needs. We're controlling 80% of health care spend. A lot of dollars are being transferred to women through generational wealth. And I think it's a huge opportunity to actually build and design solutions that have never existed before, but that there are massive markets for. So as much as it's all depressing that there's been so little funding, I think it also points to the fact that there's a lot of opportunity.
Bryan Mahoney
Yeah, I mean, again, you're speaking like a real founder. You're optimistic — that's what keeps us coming back every single day, as you find that opportunity. Was it helpful that the microbiome is something that has become, at least as a term, understood, whether it's gut health, which has received an awful lot of attention recently? Maybe not an accelerant, but is it fair to say that's probably helped people at least understand the approach that you're taking?
Priyanka Jain
Yeah, it's interesting. I would say that it's both a blessing and a curse, in the sense that yes, there are some people who understand the microbiome and who are excited about it. And definitely the microbiome science in other areas — gut, oral, plant, animal, et cetera — has helped build the tools, bring down the cost of those tools, et cetera. So that's great. The flip side of that is that there have also been a lot of doctors and patients who've been let down by other microbiome solutions. So I think sometimes we're fighting an uphill battle against that, where I always have to joke, like, we are not living in kombucha land over here. Everything we do is ordered by licensed clinicians. We're prescribing real treatment. We're giving patients real diagnoses.
Priyanka Jain
And I often say that I think the vaginal microbiome will be the first microbiome that actually translates into true clinical care, because one, it's already the leading reason that women go to the doctor, and two, doctors are already trying to test and measure what's going on. They're just not using the right tools, because they need microbiome-based tools for what they're looking at. And so it's already happening. We're just bringing the right tools to the problem. Whereas I think that in other fields, it's not already the standard that people are trying to understand the microbiome to solve the problem.
Priyanka Jain
And so in some ways, I think it's been very helpful to us, but in other ways, sometimes I joke that we should ditch the word microbiome entirely and talk about ourselves as a measurement tool for disease-causing pathogens, because that's really what we're doing. And I think that sometimes people associate the word microbiome with not being clinical, if that makes sense.
Bryan Mahoney
Yeah, it makes an awful lot of sense. And I think sometimes it's just finding the right language that makes it easier for people to find you and to be less skeptical. And there's obviously a ton of noise — not in your space necessarily, but in the health and wellness space generally — and a lot of people who are pretending to be health experts and selling an awful lot of things that aren't backed by science at all. It's easy to fall into a trap, I think.
Bryan Mahoney
I get this question an awful lot about customer acquisition and bringing people back and doing it efficiently. And I think community is a term, or education is a term, that's bandied about maybe too often, but it seems like that has really underpinned your success here. As we move into this world where LLMs are doing an awful lot more discovery for us — and I think we are using these tools as doctors to some extent — are you really reaping the benefits of the focus on content and community? I imagine it's paying real dividends now as you continue to expand your customer base. Is that fair to say?
Priyanka Jain
Totally. I mean, for us, community, content, education — that is our marketing strategy. For us, it's like, if we can educate you that you have a vaginal microbiome, and that the vaginal microbiome is related to the things you care about — whether those are vaginal infections and symptoms, whether that's fertility, whether that's menopause symptoms, the vaginal microbiome's playing a role — if you understand that, and then if you understand that a clinically validated solution like Evvy exists to understand and solve that problem, that's our sales. That's our sales strategy. That's our marketing strategy.
Priyanka Jain
But at the same time, what's so fun about that is that we get to educate women about their bodies. We get to educate them about how fertility is massively impacted by the vaginal microbiome. That when you have these infectious bacteria in the vagina, you now have infection of the reproductive tract. And you're much less likely to have an embryo implant or get pregnant if your body is in a state of infection. And it's amazing that you can take a swab at home by yourself, find that out, and then do a treatment program that has been proven to reduce those markers. We get to educate patients about that, and that obviously does the sales for us.
Priyanka Jain
And then community has been hugely important for us — both our own community on TikTok and Instagram, and we have a private Facebook group community — but then also third-party communities. There are huge communities on Reddit, Facebook groups, et cetera, of women dealing with recurrent and chronic problems, whether it's infertility or vaginal symptoms. And now what we often see is that the first comment on somebody's new post will be, well, what are your Evvy results? Where is the data that you're using to solve this?
Bryan Mahoney
Oh my god, that's got to feel good.
Priyanka Jain
Which is amazing, because the data gives people something to orient on that's objective, and then you can say, well, what worked for me is likely to work or not for you, because we actually are starting from a similar place or not. And I think that data is so often something that these communities have been lacking, and so it's been really exciting to be able to provide that tool so that people can have more educated conversations.
Bryan Mahoney
Yeah, it's got to be a real proud moment for you to see some of those comments where people are referring to you by name. And from what I've read, the results seem spectacular. And I think those results, plus the fact that you have built the community that you've built, give you permission to continue to expand in terms of products and categories. And I promise to get you out on time. I know you're busy and your team needs you.
Priyanka Jain
Don't worry.
Bryan Mahoney
But I'm curious, as you've achieved so much success here, what are you excited about for the back half of the year? What's coming next?
Priyanka Jain
Yes, we have a lot coming next. We have some exciting announcements that will come in the next couple of months across the growth of the business itself. Today we serve over 100,000 patients and we work with over 2,000 doctors across the country. And we have a lot more we're going to be able to share there. And then also on the fertility side, we've been running a prospective study using Evvy's test in IVF clinics. And we have some really exciting results from that study that we are going to be sharing later this year, and ways that fertility patients and doctors can leverage the platform to hopefully help improve outcomes in that space.
Bryan Mahoney
Okay, so what's the easiest way for us to follow along on that journey? On the website, follow you on LinkedIn — where should we find you?
Priyanka Jain
Yes, Evvy is at Evvy on Instagram. We are @evvybio on TikTok. If you have not checked that out, it is hilarious and amazing, and I highly recommend it. And then we are also on LinkedIn. I'm on LinkedIn, Evvy's on LinkedIn, and we're sharing all the fun updates and stories along the way. But to anyone who is trying to start a company in this space, I think that we need you. So there's a lot to do.
Bryan Mahoney
Yeah, there's room for everyone. Well, I think that's a great place to wrap us up, on time as promised. Thank you so much for joining me here today. Thank you so much for starting Evvy and for sharing these results. I find it really inspiring. I always love talking to founders who are taking on really difficult challenges in really interesting spaces. And I really enjoyed doing the research leading up to this. I knew I was going to enjoy chatting with you, and you absolutely delivered.
Priyanka Jain
Well, thank you so much. I really appreciate you having me, and for the amazing platform that you have built as well.
Bryan Mahoney
Thanks so much. All right, I'll speak to you soon.